利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.02 秒)

    HCV INHIBITIING SULFONAMIDES
    3.
    发明公开
    HCV INHIBITIING SULFONAMIDES 有权
    HCV耐磺胺

    公开(公告)号：EP1670448A1

    公开(公告)日：2006-06-21

    申请号：EP04766871.0

    申请日：2004-09-30

    申请人： Tibotec Pharmaceuticals Ltd.

    发明人： SIMMEN, Kenneth Alan ,  VAN ACKER, Koenraad Lodewijk August ,  WIGERINCK, Piet Tom Bert Paul ,  SURLERAUX, Dominique Louis Nestor Ghislain ,  DAMS, Géry Karel Julia ,  QUIRYNEN, Ludo Maria Marcel ,  HERTOGS, Kurt ,  PAUWELS, Rudi Wilfried Jan

    IPC分类号： A61K31/18 ,  A61K31/426 ,  A61K31/421 ,  A61P31/14

    CPC分类号： A61K45/06 ,  A61K31/18 ,  A61K31/421 ,  A61K31/426 ,  A61K2300/00

    摘要： The present invention concerns sulfonamide derivatives having the general formula (I) and N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs and esters thereof, wherein Q1 is -S- or -O-; R1 is hydrogen, C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono-or di(C1-4 alkyl)amino; R2 is hydrogen or C1-6 alkyl; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4 alkyl, or arylC1-4 alkyl; R4 is hydrogen, C1-4 alkyloxycarbonyl, carboxyl, optionally mono- or disubstituted aminocarbonyl, mono- or di(C C1-4alkyl)aminocarbonyl, C3-7cycloalkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6alkyl optionally substituted with one or more substituents each independently selected from aryl, Het1, Het2, C3-7cycloalkyl, C1-4alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C1-4 alkyl)aminocarbonyl, aminosulfonyl, C1-4alkylS(=O)t, hydroxy, cyano, halogen or amino optionally mono- or di-substituted where the substituents are each independently selected from C1-4alkyl, aryl, arylC1-4 alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, Het1, Het2 Het1C1-4alkyl and Het2C1-4 alkyl; Q2 is a radical of formulae (III, IV, V, VI, VII) for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The present invention also relates to the use of said sulfonamides in pharmaceutical compositions aimed to treat or combat combined HCV and HIV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present sulfonamides with other anti-HCV agents and/or anti-HIV agents.

    MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
    4.
    发明公开
    MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS 有权
    丙型肝炎病毒的大环内酯类抑制剂

    公开(公告)号：EP1919899A1

    公开(公告)日：2008-05-14

    申请号：EP06778070.0

    申请日：2006-07-28

    申请人： Tibotec Pharmaceuticals Ltd. ,  MEDIVIR AB

    发明人： DE KOCK, Herman Augustinus ,  SIMMEN, Kenneth Alan ,  JÖNSSON, Carl Erik Daniel ,  AYESA ALVAREZ, Susana ,  CLASSON, Björn Olof ,  NILSSON, Karl Magnus ,  ROSENQUIST, Åsa Annica Kristina ,  SAMUELSSON, Bengt Bertil ,  WALLBERG, Hans Kristian

    IPC分类号： C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  A61K31/538 ,  A61P31/14

    CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D413/12 ,  C07D487/04

    摘要： Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from formula (II) wherein said ring system may optionally be substituted with 1-3 substituents; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each of which may be optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from N, O or S, and being optionally substituted with 1-3 substituents pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

    摘要翻译： 式（I）的HCV复制抑制剂及其N-氧化物，盐或立体异构体，其中每个虚线表示任选的双键; X是N，CH，其中X带有一个双键，它是C; R1是-OR6，-NH-SO2R7; R2是氢，并且其中X是C或CH，R2也可以是C1-6烷基; R3是氢，C1-6烷基，C1-6烷氧基C1-6烷基或C3-7环烷基; n是3,4,5或6; R 4和R 5与它们所连接的氮原子一起形成选自式（II）的双环系统，其中所述环系统可以任选地被1-3个取代基取代; R6是氢; 芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或用Het取代的C 1-6烷基; R7是芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或用Het取代的C 1-6烷基; 芳基是苯基或萘基，它们中的每一个可以任选被1-3个取代基取代; Het是含有1至4个各自独立地选自N，O或S的杂原子的5或6元饱和，部分不饱和或完全不饱和的杂环，并且任选地被1-3个取代基药物组合物取代，所述药物组合物含有化合物（I） 制备化合物（I）。 还提供了式（I）的HCV抑制剂与利托那韦的生物可用组合。

    HCV INHIBITING SULFONAMIDES
    6.
    发明授权
    HCV INHIBITING SULFONAMIDES 有权
    HCV-HEMMENDE磺酰胺

    公开(公告)号：EP1670448B1

    公开(公告)日：2007-11-21

    申请号：EP04766871.0

    申请日：2004-09-30

    申请人： Tibotec Pharmaceuticals Ltd.

    发明人： SIMMEN, Kenneth Alan ,  VAN ACKER, Koenraad Lodewijk August ,  WIGERINCK, Piet Tom Bert Paul ,  SURLERAUX, Dominique Louis Nestor Ghislain ,  DAMS, Géry Karel Julia ,  QUIRYNEN, Ludo Maria Marcel ,  HERTOGS, Kurt ,  PAUWELS, Rudi Wilfried Jan

    IPC分类号： A61K31/18 ,  A61K31/426 ,  A61K31/421 ,  A61P31/14

    CPC分类号： A61K45/06 ,  A61K31/18 ,  A61K31/421 ,  A61K31/426 ,  A61K2300/00

    摘要： The present invention concerns sulfonamide derivatives having the general formula (I) and N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs and esters thereof, wherein Q1 is -S- or -O-; R1 is hydrogen, C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono-or di(C1-4 alkyl)amino; R2 is hydrogen or C1-6 alkyl; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4 alkyl, or arylC1-4 alkyl; R4 is hydrogen, C1-4 alkyloxycarbonyl, carboxyl, optionally mono- or disubstituted aminocarbonyl, mono- or di(C C1-4alkyl)aminocarbonyl, C3-7cycloalkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6alkyl optionally substituted with one or more substituents each independently selected from aryl, Het , Het , C3-7cycloalkyl, C1-4alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C1-4 alkyl)aminocarbonyl, aminosulfonyl, C1-4alkylS(=O)t, hydroxy, cyano, halogen or amino optionally mono- or di-substituted where the substituents are each independently selected from C1-4alkyl, aryl, arylC1-4 alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, Het , Het Het C1-4alkyl and Het C1-4 alkyl; Q2 is a radical of formulae (III, IV, V, VI, VII) for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The present invention also relates to the use of said sulfonamides in pharmaceutical compositions aimed to treat or combat combined HCV and HIV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present sulfonamides with other anti-HCV agents and/or anti-HIV agents.

    MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
    8.
    发明公开
    MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS 有权
    丙型肝炎病毒的大环内酯类抑制剂

    公开(公告)号：EP1919898A1

    公开(公告)日：2008-05-14

    申请号：EP06778069.2

    申请日：2006-07-28

    申请人： Tibotec Pharmaceuticals Ltd. ,  MEDIVIR AB

    发明人： RABOISSON, Pierre Jean-Marie Bernard ,  DE KOCK, Herman Augustinus ,  SIMMEN, Kenneth Alan ,  JÖNSSON, Carl Erik Daniel ,  NILSSON, Karl Magnus ,  ROSENQUIST, Åsa Annica Kristina ,  SAMUELSSON, Bengt Bertil ,  ANTONOV, Dmitry ,  SALVADOR ODÉN, Lourdes ,  AYESA ALVAREZ, Susana ,  CLASSON, Björn Olof

    IPC分类号： C07D401/12 ,  C07D403/12 ,  C07D245/04 ,  A61K31/4523 ,  A61P31/14

    CPC分类号： C07D401/12 ,  C07D225/04 ,  C07D245/04 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04

    摘要： Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

    摘要翻译： 式（I）的HCV复制抑制剂及其N-氧化物，盐或立体异构体，其中每条虚线（由------表示）表示任选的双键; X是N，CH，其中X带有一个双键，它是C; R1是-OR6，-NH-SO2R7; R2是氢，并且其中X是C或CH，R2也可以是C1-6烷基; R3是氢，C1-6烷基，C1-6烷氧基C1-6烷基或C3-7环烷基; n是3,4,5或6; R4和R5彼此独立地为氢，卤素，羟基，硝基，氰基，羧基，C1-6烷基，C1-6烷氧基，C1-6烷氧基C1-6烷基，C1-6烷基羰基，C1-6烷氧基羰基，氨基，叠氮基，巯基， C 1-6烷硫基，多卤代C 1-6烷基，芳基或Het; W是芳基或Het; R6是氢; 芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或用Het取代的C 1-6烷基; R7是芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或用Het取代的C 1-6烷基; 芳基是苯基或萘基，各自任选被1-3个取代基取代; Het是含有1-4个各自独立地选自N，O或S的杂原子且任选被1-3个取代基取代的5或6元饱和，部分不饱和或完全不饱和的杂环; 含有化合物（I）的药物组合物和用于制备化合物（I）的方法。 还提供了式（I）的HCV抑制剂与利托那韦的生物可用组合。